|Bid||114.49 x 100|
|Ask||116.78 x 200|
|Day's Range||116.35 - 117.18|
|52 Week Range||94.42 - 127.64|
|PE Ratio (TTM)||43.85|
|Earnings Date||Jul 26, 2017 - Jul 31, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||141.71|
Conservatively, this cancer drug is expected to generate between $8 billion and $8.3 billion in full-year sales.
Here are three out-of-favor companies that deserve much more attention from investors.
It's Celgene versus Bristol-Myers Squibb in a head-to-head matchup. Which drug stock wins as the better pick for long-term investors?